These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38582179)

  • 21. Ocular drug delivery systems: An overview.
    Patel A; Cholkar K; Agrahari V; Mitra AK
    World J Pharmacol; 2013; 2(2):47-64. PubMed ID: 25590022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aqueous eye drops containing drug/cyclodextrin nanoparticles deliver therapeutic drug concentrations to both anterior and posterior segment.
    Loftsson T; Stefánsson E
    Acta Ophthalmol; 2022 Feb; 100(1):7-25. PubMed ID: 33876553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation.
    Rodrigues GA; Lutz D; Shen J; Yuan X; Shen H; Cunningham J; Rivers HM
    Pharm Res; 2018 Oct; 35(12):245. PubMed ID: 30374744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.
    Wu Y; Li X; Fu X; Huang X; Zhang S; Zhao N; Ma X; Saiding Q; Yang M; Tao W; Zhou X; Huang J
    Adv Sci (Weinh); 2024 Aug; 11(32):e2403399. PubMed ID: 39031809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrogels in ophthalmic applications.
    Kirchhof S; Goepferich AM; Brandl FP
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):227-38. PubMed ID: 26032290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies.
    Kannan RM; Pitha I; Parikh KS
    Adv Drug Deliv Rev; 2023 Sep; 200():115005. PubMed ID: 37419213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases.
    Onugwu AL; Nwagwu CS; Onugwu OS; Echezona AC; Agbo CP; Ihim SA; Emeh P; Nnamani PO; Attama AA; Khutoryanskiy VV
    J Control Release; 2023 Feb; 354():465-488. PubMed ID: 36642250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical challenges for developing long acting intravitreal medicines.
    Awwad S; Henein C; Ibeanu N; Khaw PT; Brocchini S
    Eur J Pharm Biopharm; 2020 Aug; 153():130-149. PubMed ID: 32445965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.
    Alshaikh RA; Waeber C; Ryan KB
    Adv Drug Deliv Rev; 2022 Aug; 187():114342. PubMed ID: 35569559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in ocular drug delivery: emphasis on the posterior segment.
    Kang-Mieler JJ; Osswald CR; Mieler WF
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1647-60. PubMed ID: 24975820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prodrugs and nanomicelles to overcome ocular barriers for drug penetration.
    Gote V; Ansong M; Pal D
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):885-906. PubMed ID: 32729364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular pharmacology.
    Novack GD; Robin AL
    J Clin Pharmacol; 2016 May; 56(5):517-27. PubMed ID: 26360129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.
    Tsung TH; Tsai YC; Lee HP; Chen YH; Lu DW
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nano-based ocular drug delivery systems: an insight into the preclinical/clinical studies and their potential in the treatment of posterior ocular diseases.
    Su Y; Fan X; Pang Y
    Biomater Sci; 2023 Jun; 11(13):4490-4507. PubMed ID: 37222479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
    Wang R; Gao Y; Liu A; Zhai G
    J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.
    Gaballa SA; Kompella UB; Elgarhy O; Alqahtani AM; Pierscionek B; Alany RG; Abdelkader H
    Drug Deliv Transl Res; 2021 Jun; 11(3):866-893. PubMed ID: 32901367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanotherapy for posterior eye diseases.
    Kaur IP; Kakkar S
    J Control Release; 2014 Nov; 193():100-12. PubMed ID: 24862316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanocarriers for ocular drug delivery: Recent advances and future opportunities.
    Amrutkar CS; Patil SB
    Indian J Ophthalmol; 2023 Jun; 71(6):2355-2366. PubMed ID: 37322644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.